Literature DB >> 30706387

Basic Concepts in Viral Vector-Mediated Gene Therapy.

Matthew J Benskey1, Ivette M Sandoval1,2, Kathryn Miller1, Rhyomi L Sellnow1, Aysegul Gezer1, Nathan C Kuhn1, Roslyn Vashon1, Fredric P Manfredsson3,4.   

Abstract

Today any researcher with the desire can easily purchase a viral vector. However, despite the availability of viral vectors themselves, the requisite knowledge that is absolutely essential to conducting a gene therapy experiment remains somewhat obscure and esoteric. To utilize viral vectors to their full potential, a large number of decisions must be made, in some instances prior to even obtaining the vector itself. For example, critical decisions include selection of the proper virus, selection of the proper expression cassette, whether to produce or purchase a viral vector, proper viral handling and storage, the most appropriate delivery method, selecting the proper controls, how to ensure your virus is expressing properly, and many other complex decisions that are essential to performing a successful gene therapy experiment. The need to make so many important decisions can be overwhelming and potentially prohibitive, especially to the novice gene therapist. In order to aid in this challenging process, here we provide an overview of basic gene therapy modalities and a decision tree that can be used to make oneself aware of the options available to the beginning gene therapist. This information can be used as a road map to help navigate the complex and perhaps confusing process of designing a successful gene therapy experiment.

Entities:  

Keywords:  Adeno-associated virus; Adenovirus; Gene therapy; Herpes-simplex virus; Lentivirus; Viral vector

Mesh:

Year:  2019        PMID: 30706387     DOI: 10.1007/978-1-4939-9065-8_1

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  3 in total

Review 1.  Emerging therapeutic potential of adeno-associated virus-mediated gene therapy in liver fibrosis.

Authors:  Fang-Tian Bu; Peng-Cheng Jia; Yan Zhu; Ya-Ru Yang; Hong-Wu Meng; Yi-Hui Bi; Cheng Huang; Jun Li
Journal:  Mol Ther Methods Clin Dev       Date:  2022-06-22       Impact factor: 5.849

2.  Protocol for In Vivo Evaluation and Use of Destabilizing Domains in the Eye, Liver, and Beyond.

Authors:  Prerana Ramadurgum; Steffi Daniel; John D Hulleman
Journal:  STAR Protoc       Date:  2020-08-27

3.  Clinical potential of angiogenic therapy and cellular reprogramming.

Authors:  Christopher T Ryan; Vivek Patel; Todd K Rosengart
Journal:  JTCVS Open       Date:  2021-03-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.